Tapentadol
Vertebral Column Disorder
Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Grünenthal GmbH
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01838616CT.gov Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component. | — | Completed | — | — | — |
NCT01124604CT.gov An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vertebral Column Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tapentadol (this asset) | Grünenthal GmbH | Approved | BB · 67 |
| Oxycodone | Grünenthal GmbH | P4 | BBB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Nepenthe | MedtronicNeuro | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Propofol | Medical College of Wisconsin | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Celestone | Pain Management Center of Paducah | P4 | BB |
+31 more in the Vertebral Column Disorder cohort
Other indications for Tapentadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis | — | P4 | BB · 71 |
| Diabetic Neuropathy | — | P3 | BB · 65 |
| Chronic Pain Syndrome | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Tapentadol in Vertebral Column Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/tapentadol-vertebral-column-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →